AP

Ashwini Purohit

Active Director Director DIN 10739315
DIN 10739315 First appointment Aug 2024
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 2024
Shareholding value •••• Premium profile

About Ashwini Purohit

Data last updated:

Ashwini Purohit is a Director at Iki Pharma Global Private Limited (since 2024). Iki Pharma Global Private Limited reported revenue of ₹8,000 (FY 2025).

DIN 10739315
Primary Designation Director
First Appointment 12 Aug 2024
Oldest Company Age 2 yrs
Largest company Iki Pharma Global Private Limited · ₹8,000 (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Iki Pharma Global Private Limited U46497MP2024PTC072529
Director12 Aug 20242024₹8,000 (FY 2025)Active

Board colleagues of Ashwini Purohit

NameDINCompanyDesignation
Akshay Purohit10739314Iki Pharma Global Private LimitedDirector

Directorship timeline

Open interactive timeline →
Iki Pharma Global Private Limited
Premium access

Shareholding and investment profile for Ashwini Purohit

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ashwini Purohit

Ashwini Purohit currently holds 1 directorship: Iki Pharma Global Private Limited (Director, since 12 Aug 2024, revenue ₹8,000 (FY 2025)).

Ashwini Purohit was first appointed on 12 Aug 2024 as Director at Iki Pharma Global Private Limited.

The current boards of Ashwini Purohit's companies include Akshay Purohit (Iki Pharma Global Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available